The potential treatment will utilize the company’s lead oncology product, SL052, with various immunotherapeutic agents. Research has shown that photodynamic therapy (PDT) can augment the therapeutic effects of immunomodulators such as antibodies, antigens, cytokines and immunoadjuvants in cancer patients.
Under the terms of the agreement, the BCCA will investigate therapeutic and mechanistic aspects of anti-tumor effects achieved by combining PDT based on Quest’s photosensitizer, SL052, with various immunotherapeutic agents.